PL1745075T3 - Peptydy wiążące poli-N-acetyloglukozaminę (PNAG/DPNAG) i sposoby ich zastosowania - Google Patents

Peptydy wiążące poli-N-acetyloglukozaminę (PNAG/DPNAG) i sposoby ich zastosowania

Info

Publication number
PL1745075T3
PL1745075T3 PL05770709T PL05770709T PL1745075T3 PL 1745075 T3 PL1745075 T3 PL 1745075T3 PL 05770709 T PL05770709 T PL 05770709T PL 05770709 T PL05770709 T PL 05770709T PL 1745075 T3 PL1745075 T3 PL 1745075T3
Authority
PL
Poland
Prior art keywords
dpnag
pnag
poly
methods
binding peptides
Prior art date
Application number
PL05770709T
Other languages
English (en)
Inventor
Gerald B Pier
Casie Anne Kelly-Quintos
Lisa Cavacini
Marshall R Posner
Original Assignee
Brigham & Womens Hospital Inc
Beth Israel Deaconess Medical Ct Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital Inc, Beth Israel Deaconess Medical Ct Inc filed Critical Brigham & Womens Hospital Inc
Publication of PL1745075T3 publication Critical patent/PL1745075T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL05770709T 2004-04-21 2005-04-21 Peptydy wiążące poli-N-acetyloglukozaminę (PNAG/DPNAG) i sposoby ich zastosowania PL1745075T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56410504P 2004-04-21 2004-04-21
EP05770709A EP1745075B1 (en) 2004-04-21 2005-04-21 Poly-n-acetyl glucosamine (pnag/dpnag)-binding peptides and methods of use thereof
PCT/US2005/013694 WO2005103084A2 (en) 2004-04-21 2005-04-21 Poly-n-acetyl glucosamine (pnag/dpnag)-binding peptides and methods of use thereof

Publications (1)

Publication Number Publication Date
PL1745075T3 true PL1745075T3 (pl) 2013-09-30

Family

ID=35197541

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05770709T PL1745075T3 (pl) 2004-04-21 2005-04-21 Peptydy wiążące poli-N-acetyloglukozaminę (PNAG/DPNAG) i sposoby ich zastosowania

Country Status (12)

Country Link
US (13) US7786255B2 (pl)
EP (6) EP2455402A1 (pl)
JP (2) JP5080243B2 (pl)
CN (1) CN101001874B (pl)
AU (1) AU2005236068C1 (pl)
CA (1) CA2567748A1 (pl)
DK (1) DK1745075T3 (pl)
ES (2) ES2415358T3 (pl)
PL (1) PL1745075T3 (pl)
PT (1) PT1745075E (pl)
SI (1) SI1745075T1 (pl)
WO (1) WO2005103084A2 (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252828B2 (en) 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US7047058B1 (en) 2001-02-06 2006-05-16 Medrad, Inc. Apparatuses, systems and methods for extravasation detection
WO2004043405A2 (en) 2002-11-12 2004-05-27 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
AU2003290867A1 (en) 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
PL1745075T3 (pl) 2004-04-21 2013-09-30 Brigham & Womens Hospital Inc Peptydy wiążące poli-N-acetyloglukozaminę (PNAG/DPNAG) i sposoby ich zastosowania
DK2027155T3 (en) * 2006-06-06 2016-05-09 Crucell Holland Bv HUMAN BINDING MOLECULES with killer activity against staphylococci and uses thereof
US7960518B2 (en) 2006-06-06 2011-06-14 Crucell Holland B.V. Human binding molecules having killing activity against enterococci and uses thereof
AU2012268821B2 (en) * 2006-06-06 2016-06-02 Janssen Vaccines & Prevention B.V. Human binding molecules having killing activity against staphylococci and uses thereof
WO2009142738A2 (en) * 2008-05-21 2009-11-26 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
CN102159540B (zh) 2008-07-21 2015-08-12 布赖汉姆妇女医院 与合成的β-1,6葡糖胺寡糖相关的方法和组合物
US9556281B2 (en) 2011-08-15 2017-01-31 The University Of Chicago Compositions and methods related to antibodies to staphylococcal protein A
US10987017B2 (en) 2011-09-02 2021-04-27 Battelle Memorial Institute Distributed extravasation detecton system
WO2013075740A1 (en) 2011-11-23 2013-05-30 Sanofi Antibody purification method
US20150086601A1 (en) * 2012-05-07 2015-03-26 Sanofi Methods for preventing biofilm formation
ES2826000T3 (es) * 2012-05-30 2021-05-17 Brigham & Womens Hospital Inc Composiciones de polisacárido y métodos de uso
JP2015526474A (ja) * 2012-08-24 2015-09-10 サノフイ ポリ−ｎ−アセチルグルコサミン（ｐｎａｇ）発現細菌感染を予防または処置するための抗ｐｎａｇモノクローナル抗体およびその使用
JPWO2014050518A1 (ja) 2012-09-28 2016-08-22 日本電気株式会社 情報処理装置、情報処理方法および情報処理プログラム
EP2912058A1 (en) 2012-10-23 2015-09-02 The Board of Regents of The University of Texas System Antibodies with engineered igg fc domains
EP2975054A4 (en) 2013-03-12 2016-11-23 Zenyaku Kogyo Kk ANTIBODIES TO STAPHYLOKOKEN, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF
DK2994485T3 (en) 2013-05-06 2018-04-23 Sanofi Sa CONTINUOUS MULTIPLE STEP PROCEDURE FOR PURIFICATION OF ANTIBODIES
EP2889311B1 (en) * 2013-12-30 2018-03-21 Albert-Ludwigs-Universität Freiburg Opsonic and protective monoclonal antibodies against gram-positive pathogens
CN109862784A (zh) 2016-08-24 2019-06-07 特尼奥生物股份有限公司 产生经修饰的仅有重链的抗体的转基因非人动物
US11597774B2 (en) 2017-05-04 2023-03-07 City Of Hope Antibody variable domains and antibody constructs
EP3546475A1 (en) 2018-03-27 2019-10-02 Sanofi Full flow-through process for purifying recombinant proteins
US12397014B2 (en) 2019-02-05 2025-08-26 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis
JP2022519631A (ja) 2019-02-12 2022-03-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 補体および標的抗原に結合する二重特異性抗体を使用するための組成物および方法
CN110184231B (zh) * 2019-05-31 2021-02-12 杭州丰海生物科技有限公司 一种胞外分泌pnag多糖的重组枯草芽孢杆菌及其应用
US12528882B2 (en) 2019-09-13 2026-01-20 The University Of Chicago Methods and compositions for treating staphylococcal infections
US11173199B2 (en) 2019-11-13 2021-11-16 Alopexx Inc. Low contaminant compositions
CN114845731A (zh) * 2019-11-22 2022-08-02 阿洛珀希有限公司 针对包含pnag的微生物提供连续治疗的方法
US10828360B1 (en) 2020-02-04 2020-11-10 OneBioPharma, Inc. Methods for inhibiting biofilm formation
US20260015434A1 (en) * 2022-03-11 2026-01-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Antibody materials and methods targeting microbial polysaccharides
CN120082492A (zh) * 2025-02-19 2025-06-03 江南大学 一种发酵合成多聚β-(1,6)-N-乙酰氨基葡萄糖胺多糖的重组谷氨酸棒状杆菌的构建方法

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US213668A (en) 1879-03-25 Improvement in ice-making apparatus
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
JPS5452794A (en) 1977-09-30 1979-04-25 Kousaku Yoshida Extracting of polysacchride from capusle containing epidermis staphylococus
US4285936A (en) 1979-12-10 1981-08-25 The United States Of America As Represented By The Secretary Of The Army Method for producing a vaccine against bacterial infections caused by pseudomonas aeruginosa
US4355023A (en) 1980-09-30 1982-10-19 The Massachusetts General Hospital Antibody fragment compositions and process
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4443549A (en) 1981-10-19 1984-04-17 Molecular Genetics, Inc. Production of monoclonal antibodies against bacterial adhesins
US4470925A (en) 1982-05-05 1984-09-11 E. I. Du Pont De Nemours And Company Immunoglobulin half-molecules and process for producing hybrid antibodies
US4462334A (en) 1982-08-19 1984-07-31 Kim Ho K Solar animal structure
US4465776A (en) * 1982-09-27 1984-08-14 Research Corporation Monoclonal antibodies to vitamin B6 and immunoassay method
US4652448A (en) 1982-10-07 1987-03-24 Molecular Genetics, Inc. Use of monoclonal antibodies against bacterial adhesins
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4578458A (en) 1983-03-23 1986-03-25 Brigham And Women's Hospital Mucoid exopolysaccharide vaccine against Pseudomonas aeruginosa
DK219084D0 (da) 1984-05-02 1984-05-02 Frederik Carl Peter Lindberg Antigen
JPS6191131A (ja) 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd 医薬品の吸着防止方法および組成物
GB8426463D0 (en) 1984-10-19 1984-11-28 Technology Licence Co Ltd Monoclonal antibodies
NZ214503A (en) 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
FR2581877B1 (fr) 1985-05-14 1987-12-18 Louvain Universite Catholique Conjugue constitue d'une adhesine de paroi de s. mutans, de nature proteique et d'un polysaccharide de s. mutans, sa preparation et son utilisation notamment dans des vaccins anti-caries
US4786592A (en) 1986-06-18 1988-11-22 Scripps Clinic And Research Foundation Neisseria gonorrhoeae lectin useful as a vaccine and diagnostic marker and means for producing this lectin
US5589591A (en) 1986-07-03 1996-12-31 Advanced Magnetics, Inc. Endotoxin-free polysaccharides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8621910D0 (en) 1986-09-11 1986-10-15 Technology Licence Co Ltd Monoclonal antibodies
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
FR2619122B1 (fr) 1987-08-03 1990-03-09 Pasteur Institut Procede d'obtention de polyosides capsulaires de staphylocoques, polyosides obtenus, applications de ces polyosides et souches pour la mise en oeuvre du procede
US4859449A (en) 1987-09-14 1989-08-22 Center For Molecular Medicine And Immunology Modified antibodies for enhanced hepatocyte clearance
CA1340506C (en) 1987-11-24 1999-04-20 Nicholas H. Carbonetti Production of gonorrheal pi proteins and vaccines
US5055455A (en) 1988-09-28 1991-10-08 Brigham And Women's Hospital Capsular polysaccharide adhesin antigen, preparation, purification and use
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
FR2640628A1 (fr) 1988-12-16 1990-06-22 Commissariat Energie Atomique Oligosaccharides lies (beta)-(1 -> 6) en particulier des 2-acetamido-2-desoxy-glucoses ou - galactoses et leur preparation
AU640118B2 (en) 1988-12-19 1993-08-19 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur Meningococcal class 1 outer-membrane protein vaccine
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5571511A (en) 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens
DE69230037T2 (de) 1991-07-12 2000-01-05 Pfizer Inc., New York Kontinuierliche zellinie sowie impfstoff gegen geflügelinfektion mit kokkidien
ES2198405T3 (es) 1991-11-22 2004-02-01 Nabi Biopharmaceuticals Antigenos de superficie de tipo i asociados a staphylococcus epidermis.
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5872215A (en) * 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
AU667069B2 (en) 1991-12-06 1996-03-07 North Shore University Hospital Research Corporation Method of reducing medical device related infections
DE69329642T3 (de) 1992-03-19 2009-05-20 Henry M. Jackson Foundation For The Advancement Of Military Medicine Breitreaktive opsonische antikörper die mit gemeinsamen antigenen von staphylococcus reagieren
US5688516A (en) 1992-11-12 1997-11-18 Board Of Regents, The University Of Texas System Non-glycopeptide antimicrobial agents in combination with an anticoagulant, an antithrombotic or a chelating agent, and their uses in, for example, the preparation of medical devices
US5362754A (en) 1992-11-12 1994-11-08 Univ. Of Tx Md Anderson Cancer Center M-EDTA pharmaceutical preparations and uses thereof
EP0680337A4 (en) 1993-01-12 1997-07-30 Anthony George Gristina METHODS AND COMPOSITIONS FOR DIRECT APPLICATION WITH HIGH CONCENTRATION OF ANTIBODIES, PRODUCING PASSIVE IMMUNITY.
US5718694A (en) 1993-11-09 1998-02-17 The Board Of Regents Of The University Of Nebraska Inhibition of adherence of microorganisms to biomaterial surfaces by treatment with carbohydrates
US5858350A (en) 1993-12-01 1999-01-12 Marine Polymer Technologies Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system
EP0804249A2 (en) 1994-03-15 1997-11-05 Brown University Research Foundation Polymeric gene delivery system
HU221001B1 (hu) * 1994-03-17 2002-07-29 Merck Patent Gmbh. Egyláncú anti-EGFR Fv-k és anti-EGFR ellenanyagok
US5945311A (en) 1994-06-03 1999-08-31 GSF--Forschungszentrumfur Umweltund Gesundheit Method for producing heterologous bi-specific antibodies
JPH0840932A (ja) 1994-07-29 1996-02-13 Kitasato Inst:The スタフイロコッカス属菌感染症の予防ワクチン及び治療用抗体並びにそれの製造法
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5830539A (en) 1995-11-17 1998-11-03 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Methods for functionalizing and coating substrates and devices made according to the methods
US6245735B1 (en) 1996-07-29 2001-06-12 The Brigham And Women's Hospital, Inc. Methods and products for treating pseudomonas infection
EP0826696B1 (de) 1996-09-03 2002-05-29 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität
CZ106299A3 (cs) * 1996-09-26 1999-08-11 Chugai Seiyaku Kabushiki Kaisha Protilátky proti proteinu příbuznému s lidským parathyroidálním hormonem
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
TW586934B (en) 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
US5989542A (en) 1997-08-20 1999-11-23 Brigham And Women's Hospital, Inc. Capsular polysaccharides from enterococci
IT1298539B1 (it) 1998-02-03 2000-01-12 Bracco Spa Metodo per la determinazione di infezioni da protesi
JP2002511259A (ja) * 1998-04-09 2002-04-16 ジェンセット ５’ｅｓｔおよびコードされるヒトタンパク質
WO2000002745A1 (en) 1998-07-11 2000-01-20 Mile High Marketing Limited Vehicle seat, vehicle seat table and vehicle communication system
DE69938784D1 (de) * 1998-07-15 2008-07-03 Brigham & Womens Hospital Polysaccharid-impfstoff gegen staphylokokken infektionen
US7252828B2 (en) 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
EP1140229B1 (en) 1998-12-16 2010-10-06 Nederlandse Organisatie voor toegepast -natuurwetenschappelijk onderzoek TNO Acidic superabsorbent polysaccharides
WO2002094983A2 (en) 2001-05-16 2002-11-28 The Children's Hospital Of Philadelphia Dna-antibody complexes to enhance gene transfer
US7119172B2 (en) 2001-05-21 2006-10-10 The Brigham And Women's Hospital, Inc. P. aeruginosa mucoid exopolysaccharide specific binding peptides
WO2002094854A2 (en) 2001-05-21 2002-11-28 The Brigham And Women's Hospital, Inc. P.aeruginosa mucoid exopolysaccharide specific binding peptides
AU2002351208A1 (en) 2001-12-03 2003-06-17 Abgenix, Inc. Antibodies against carbonic anhydrase IX (CA IX) tumor antigen
EP1455817B1 (en) 2001-12-11 2008-12-31 Merck & Co., Inc. Staphylococcus aureus exopolysaccharide and process
EP1470146B8 (en) * 2001-12-28 2007-09-12 Amgen Fremont Inc. Antibodies against the muc18 antigen
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
AU2003218456A1 (en) 2002-04-01 2003-10-20 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
AU2003279308A1 (en) 2002-11-04 2004-06-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 73a (gpr73a)
WO2004043405A2 (en) * 2002-11-12 2004-05-27 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
AU2003290867A1 (en) * 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
PL1745075T3 (pl) 2004-04-21 2013-09-30 Brigham & Womens Hospital Inc Peptydy wiążące poli-N-acetyloglukozaminę (PNAG/DPNAG) i sposoby ich zastosowania
US8510225B2 (en) 2004-09-01 2013-08-13 Research In Motion Limited Split channel authenticity queries in multi-party dialog
WO2006070370A2 (en) 2004-12-29 2006-07-06 Hadasit Medical Research Services & Development Limited Stem cells culture systems
AR060187A1 (es) 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Composicion inmunogenica
CN102159540B (zh) 2008-07-21 2015-08-12 布赖汉姆妇女医院 与合成的β-1,6葡糖胺寡糖相关的方法和组合物
CA2786891C (en) 2009-02-20 2017-08-01 Meisho.Co.,Ltd Immunopotentiating composition and process for producing same
WO2012099805A2 (en) 2011-01-19 2012-07-26 Ocean Nanotech, Llc Nanoparticle based immunological stimulation
ES2826000T3 (es) 2012-05-30 2021-05-17 Brigham & Womens Hospital Inc Composiciones de polisacárido y métodos de uso
EP3608416A1 (en) 2013-01-22 2020-02-12 Imicroq, S.L. Rapid method for detection of pathogen

Also Published As

Publication number Publication date
US20190127448A1 (en) 2019-05-02
US8461319B2 (en) 2013-06-11
US8252894B2 (en) 2012-08-28
DK1745075T3 (da) 2013-06-24
US8435515B2 (en) 2013-05-07
SI1745075T1 (sl) 2013-07-31
US20210363228A1 (en) 2021-11-25
US20110002932A1 (en) 2011-01-06
JP5717582B2 (ja) 2015-05-13
AU2005236068C1 (en) 2012-08-30
US20120201834A1 (en) 2012-08-09
US20130243806A1 (en) 2013-09-19
US8350017B2 (en) 2013-01-08
EP2455400A1 (en) 2012-05-23
US9458227B2 (en) 2016-10-04
EP2439213B1 (en) 2018-12-12
JP5080243B2 (ja) 2012-11-21
HK1100369A1 (en) 2007-09-21
US20150329620A1 (en) 2015-11-19
EP2455401A1 (en) 2012-05-23
US20120196359A1 (en) 2012-08-02
JP2011224023A (ja) 2011-11-10
US7786255B2 (en) 2010-08-31
JP2008501317A (ja) 2008-01-24
ES2738112T3 (es) 2020-01-20
US20170226194A1 (en) 2017-08-10
US8912314B2 (en) 2014-12-16
US20120208270A1 (en) 2012-08-16
US20120201833A1 (en) 2012-08-09
US8410249B2 (en) 2013-04-02
AU2005236068B2 (en) 2012-04-26
CA2567748A1 (en) 2005-11-03
US8084595B2 (en) 2011-12-27
EP2455401B1 (en) 2018-01-24
EP1745075A2 (en) 2007-01-24
AU2005236068A1 (en) 2005-11-03
WO2005103084A2 (en) 2005-11-03
US10017563B2 (en) 2018-07-10
EP1745075B1 (en) 2013-04-03
EP2455402A1 (en) 2012-05-23
ES2415358T3 (es) 2013-07-25
WO2005103084A3 (en) 2006-02-16
EP2439213A1 (en) 2012-04-11
EP2468769A1 (en) 2012-06-27
EP2455400B1 (en) 2019-03-20
CN101001874A (zh) 2007-07-18
US10906962B2 (en) 2021-02-02
CN101001874B (zh) 2012-12-19
US20110274700A1 (en) 2011-11-10
US20230382980A1 (en) 2023-11-30
US20060115486A1 (en) 2006-06-01
PT1745075E (pt) 2013-06-17

Similar Documents

Publication Publication Date Title
SI1745075T1 (sl) Poli-N-acetilglukozamin (PNAG/dPNAG) vezavni peptidi in postopki za njihovo uporabo
GB2412589B (en) Hyperbaric dressing
ZA200600716B (en) Improvements in and to processes
IL190332A0 (en) Human antibodies against il13 and therapeutic uses
IL179300A0 (en) Novel-antigen-binding polypeptides and their uses
EP1757658A4 (en) RUBBER COMPOSITION AND USE THEREOF
ZA200703313B (en) Recombinant human T2 RNase and uses thereof
IL182498A0 (en) Therapeutic furopyrimidines and thienopyrimidines
IL183400A0 (en) New peptides useful as dual caspase-2/-6 inhibitors and their biological applications
EP1794589A4 (en) PROTEIN ARRAYS AND METHOD OF USE THEREOF
EP1877344A4 (en) BIOFILTER UNITS AND WATER TREATMENT PLANTS THEREWITH
IL178181A0 (en) Fungicidal mixtures and novel triazolopyrimidines
EP1871793A4 (en) PROTOONCOGEN HUMAN AND PROTEIN CODED THEREWITH
GB0426161D0 (en) Protein isolation and purification
EP1960523A4 (en) MODIFIED POREN FORMING PROTEIN TOXINS AND USE THEREOF
TWI340752B (en) Elastomer composition and molded body
SK50812005A3 (sk) Zmesi polyuretánu a gumy
ZA200704017B (en) Scarecrow-like stress-related polypeptides and methods of use in plants
EP1687330A4 (en) PEPTIDES WITH ANTIBODY EFFECT AND OTHER RELATED APPLICATIONS
PL2215908T3 (pl) 2-alkilo-cykloalk(en)ylo-karboksamidy i ich zastosowanie jako fungicydów
PT2557165T (pt) Promotores preferidos de câmbio/xilema e usos dos mesmos
GB0401182D0 (en) Improvements in and relating to conveyors
ZA200606216B (en) Modified human interferon polypeptides and their uses
EP1813671A4 (en) SOLUBLE PROTEIN AND USE THEREOF
ZA200802541B (en) Human antibodies against IL13 and therapeutic uses